AGP Pharmaceuticals: Major
Health Technology
155.48 -0.58%
Mkt Cap
43.8B
P/E (TTM)
11.71
EPS (TTM)
13.36
ROE (TTM)
26.00%
Div Yield
5.15%
AGP Limited (AGP) Financial Statements, Ratios & Dividends
About
AGP Ltd. engages in the import, marketing, export, dealership, distribution, wholesale, and manufacturing of pharmaceuticals and healthcare products. Its products include aminoglycosides, anti epileptics, anti-gout, antifibrinolytic, antiobesity, macrolides, and narcotic analgesic. The company was founded in 1989 and is headquartered in Karachi, Pakistan.
Financial Highlights
| FY2025 | FY2024 | ||
|---|---|---|---|
| Revenue | 28.89B | 25.03B | |
| Gross Profit | 16.77B | 14.17B | |
| Net Income | 3.74B | 2.67B | |
| EPS | 13.34 | 9.53 | |
| ROE | 25.87% | 21.49% | |
| ROA | 12.15% | 9.31% | |
| Gross Margin | 58.06% | 56.61% | |
| Net Margin | 12.93% | 10.66% | |
| Current Ratio | 1.01 | 1.08 | |
| DPS | 8.00 | 4.00 | |
| Free Cash Flow | 4.65B | 4.42B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Total Revenue | 28.89B | 25.03B | |
| Cost of Goods Sold | -12.12B | -10.86B | |
| Gross Profit | 16.77B | 14.17B | |
| SG&A Expenses | -8.58B | -7.01B | |
| Research & Development | -38.66M | -105.51M | |
| Depreciation | -473.65M | -355.07M | |
| Other Operating Expense | -249.45M | -101.60M | |
| Total Operating Expense | -20.95B | -17.97B | |
| Operating Income (EBIT) | 7.94B | 7.06B | |
| Interest Income | 62.53M | 71.61M | |
| Interest Expense | -1.44B | -2.69B | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | -35.76M | -31.09M | |
| Total Non-Operating Income | -1.42B | -2.65B | |
| Pre-Tax Income | 6.52B | 4.41B | |
| Income Tax | -2.19B | -1.45B | |
| Minority Interest | -599.83M | -290.87M | |
| Net Income | 3.74B | 2.67B | |
| EBITDA | 8.43B | 7.44B | |
| EPS (Basic) | 13.34 | 9.53 | |
| EPS (Diluted) | 13.34 | 9.53 | |
| Gross Margin | 58.06% | 56.61% | |
| Operating Margin | 27.48% | 28.21% | |
| EBITDA Margin | 29.19% | 29.73% | |
| Pre-Tax Margin | 22.58% | 17.62% | |
| Net Margin | 12.93% | 10.66% |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 25.87% | 21.49% | |
| Return on Assets (ROA) | 12.15% | 9.31% | |
| Return on Invested Capital | 17.68% | 12.70% | |
| Gross Margin | 58.06% | 56.61% | |
| Operating Margin | 27.48% | 28.21% | |
| EBITDA Margin | 29.19% | 29.73% | |
| Net Margin | 12.93% | 10.66% | |
| Pre-Tax Margin | 22.58% | 17.62% | |
| Liquidity | |||
| Current Ratio | 1.01 | 1.08 | |
| Quick Ratio | 0.46 | 0.43 | |
| Leverage | |||
| Debt / Equity | 0.65 | 0.81 | |
| Debt / Assets | 0.31 | 0.37 | |
| LT Debt / Equity | 0.37 | 0.57 | |
| LT Debt / Assets | 0.18 | 0.26 | |
| Net Debt | 8.65B | 9.96B | |
| Total Debt | 10.04B | 10.88B | |
| Efficiency | |||
| Asset Turnover | 0.94 | 0.87 | |
| Inventory Turnover | 2.59 | 2.72 | |
| Per Share | |||
| Book Value Per Share | 55.24 | 47.90 | |
| Tangible Book Per Share | -7.28 | -14.65 | |
| Cash Per Share | 4.94 | 3.28 | |
| Total Debt Per Share | 35.84 | 38.85 | |
| Working Capital Per Share | 0.43 | 1.91 | |
| Shares & Market | |||
| Total Shares Outstanding | 280,000,000 | 280,000,000 | |
| Market Cap | 56.88B | 47.63B | |
| Enterprise Value | 67.19B | 58.74B | |
| Employees | 1,679 | 1,574 | |
| Shareholders | 5,078 | 5,078 | |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Dividends Per Share | 8.00 | 4.00 | |
| Dividend Yield | 3.94% | 2.35% | |
| Payout Ratio | 59.97% | 41.95% | |
| Total Dividends Paid | -1.78B | -752.34M |
| FY2025 | FY2024 | ||
|---|---|---|---|
| P/E Ratio | 15.23 | 17.84 | |
| P/B Ratio | 3.68 | 3.55 | |
| P/S Ratio | 1.97 | 1.90 | |
| P/CF Ratio | 9.52 | 8.87 | |
| EV/EBITDA | 7.97 | 7.89 | |
| Market Cap | 56.88B | 47.63B | |
| Enterprise Value | 67.19B | 58.74B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 27.70B | |
| Gross Profit | 16.46B | |
| Operating Income | 7.58B | |
| Net Income | 3.74B | |
| EBIT | 7.58B | |
| Free Cash Flow | 2.58B | |
| EPS (Basic) | 13.36 | |
| Margins | ||
| Gross Margin | 59.41% | |
| Operating Margin | 27.35% | |
| Net Margin | 13.50% | |
| Returns | ||
| Return on Equity (ROE) | 26.00% | |
| ROIC | 0.19% | |
| Coverage & Debt | ||
| Interest Coverage | 5.6x | |
| Dividend Coverage | 2.64 | |
| Debt / Revenue | 0.44 | |
| Valuation & Scores | ||
| P/E (TTM) | 11.71 | |
| Sloan Ratio | 3.29 | |
| Zmijewski Score | -2.10 | |
Computed Metrics (Latest Period)
| FY2025 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 25.87% | |
| Return on Tangible Equity | -121.66% | |
| Return on Tangible Assets | 28.25% | |
| Return on Total Capital | 30.19% | |
| ROCE | 34.68% | |
| Growth | ||
| EPS Diluted Growth | 0.40% | |
| Sustainable Growth Rate | 10.36% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 8 | |
| Zmijewski Score | -2.21 | |
| Sloan Ratio | -3.16 | |
| Valuation (Computed) | ||
| Graham Number | 128.76 | |
| Tobin's Q Ratio | 1.77 | |
| Leverage & Coverage | ||
| Interest Coverage | 5.5x | |
| Total Debt / Capital | 0.39% | |
| Assets / Equity (Leverage) | 2.07 | |
| Net Debt / EBITDA | 1.03 | |
| Effective Interest Rate | 13.80% | |
| Debt / Revenue | 0.35 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 5.86 | |
| Receivables Turnover | 12.57 | |
| Dividends (Computed) | ||
| Payout Ratio | 0.60% | |
| Dividend Coverage | 3.94 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 17.21M | |
| Net Income / Employee | 2.22M | |
| Oper. Income / Employee | 4.73M | |
| Total Assets / Employee | 19.10M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 14.56B | |
| Invested Capital | 21.25B | |
| Working Capital | 121.39M | |
| Book Value Per Share | 55.24 | |
| Earnings Schedule | ||
| Next Earnings Date | 3 Mar 2027 | |
| Next Fiscal Period | 2026 | |